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Abstract
Background: In many clinical disorders, there is a relationship between the ratio of the diameter of the main
pulmonary artery (mPA) to that of the aorta (Ao) on chest computed tomography (CT). The aim of this study
was to determine if the mPA/Ao ratio at diagnosis is associated with the clinical characteristics and outcomes
in patients with idiopathic pulmonary fibrosis (IPF).
Methods: We retrospectively reviewed the diameters of the pulmonary artery and aorta on chest CT, clinical
characteristics, and results of other examinations in 303 patients at the time of initial diagnosis of IPF at our
tertiary care center between 2011 and 2015. The primary outcomes were death and lung transplantation. The
patients were followed up until June 2017.
Results: One hundred and eight patients (35.6%) died and 58 (19.1%) underwent lung transplantation during
follow-up. The mean mPA and Ao diameters were 28.3 mm and 34.0 mm, respectively, and the mean mPA/Ao
ratio was 0.84. Thirty-one patients (10.2%) had an mPA/Ao ratio > 1.0 and 182 (60.1%) had an mPA/Ao ratio > 0.8.
Patients with an mPA/Ao ratio > 0.8 had a lower DLco value than those with an mPA/Ao ratio≤ 0.8. In Kaplan-Meier
analysis, patients with an mPA/Ao ratio > 1.0 or > 0.8 had worse outcomes than those with an mPA/Ao ratio≤ 1.0
and≤ 0.8, respectively.
Conclusions: A higher mPA/Ao ratio based on 1.0 and 0.8 is associated with unfavorable prognosis in patients with IPF.
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Background
Idiopathic pulmonary fibrosis (IPF) is a chronic, progres-
sive, and fatal disease. The natural course of IPF can be
diverse, and prediction of the prognosis is difficult. Pul-
monary hypertension (PH) is common in the advanced
stages of IPF, and its presence is reported to be associated
with decreased exercise capacity and high mortality in
patients with IPF [1–3]. The definition of PH is based
on data obtained by right heart catheterization [4],
which is an invasive and costly procedure. Furthermore,
transthoracic echocardiography is known to be a useful
noninvasive method when screening for PH [5, 6] but is
also a costly method and has limited accuracy for
assessment of PH in patients with IPF [7, 8].
Measurement of the diameter of the main pulmonary
artery (mPA) on CT of the chest has been reported to
predict the presence of PH in patients with parenchymal
lung disease, such as IPF or chronic obstructive pulmo-
nary disease (COPD) [9–12], and the ratio of the dia-
meter of the mPA to that of the aorta (Ao) > 1 has been
reported to indicate a very high probability of PH [13].
Furthermore, in a previous study conducted in the US,
an mPA/Ao ratio > 1 was associated with worse out-
comes in patients with IPF, and measurement of the
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: dobie@yuhs.ac
Division of Pulmonology, Department of Internal Medicine, Severance
Hospital, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu,
Seoul 03722, Republic of Korea
Choi et al. BMC Pulmonary Medicine           (2019) 19:81 
https://doi.org/10.1186/s12890-019-0843-5
mPA/Ao ratio on chest CT assisted in evaluation of the
risk and prognosis in these patients [14]. However,
another study reported that the diameter of the mPA,
that of the Ao, and the mPA/Ao ratio can vary accor-
ding to ethnicity and lifestyle [15], implying that the
mPA/Ao ratio may be different in Asian patients with
IPF from that in their Western counterparts. The aim
of this study was to determine if there is an association
of the mPA/Ao ratio with clinical characteristics and
outcomes in Korean patients with IPF.
Methods
Study design
We retrospectively identified 460 patients who were
diagnosed or referred with IPF at our tertiary care
university hospital in South Korea between January 2011
and December 2015. The diagnosis was confirmed cli-
nically in 296 patients and pathologically in 164 patients
by consensus among multidisciplinary specialists accor-
ding to the 2011 American Thoracic Society/European
Respiratory Society/Japanese Respiratory Society/Latin
American Thoracic Association guidelines [2]. One
hundred and fifty-seven patients who did not attend
for follow-up after diagnosis were excluded, leaving
data for 303 patients with IPF available for inclusion
in the analysis.
The patients’ initial CT scans of the chest and medical
records, including baseline characteristics, laboratory
findings, 6-min walking distance, pulmonary function
test (PFT) results at the time of diagnosis, and echocar-
diographic findings were reviewed to evaluate their asso-
ciations with the mPA/Ao ratio. The primary outcomes
were death and lung transplantation. The study protocol
was approved by the institutional review board at Severance
Hospital (IRB 4-2017-1219) and the need for informed
consent was waived.
Measurements
CT scans of the chest were performed in all the patients
at the time of initial diagnosis of IPF. The diameter of
the mPA and that of the ascending Ao were measured at
the level of bifurcation of the pulmonary artery. The
diameter of the mPA was defined as the widest diameter
perpendicular to the long axis of the mPA and measure-
ment of the ascending Ao was taken as the transverse
diameter (Fig. 1). Two reviewers who were blinded to
the clinical data measured the mPA and Ao on the same
CT image independently, and the average of two
measurements was used to calculate the mPA/Ao ratio.
The value of inter-observer correlation coefficient was
0.84 (95% confidence interval (CI), 0.80–0.87) for mPA,
and 0.92 (95% CI, 0.90–0.94) for Ao.
We divided the patients into two groups according to
whether they had an mPA/Ao ratio ≤ 1 or > 1 on the
initial chest CT. An mPA/Ao ratio > 1 was considered to
indicate the presence of PH [13]. The patients were then
grouped according to whether the mPA/Ao ratio was
≤0.8 or > 0.8 because of a previous report indicating that
Korean patients with COPD and an mPA/Ao ratio > 0.8
had clinical characteristics that differed from those in
their counterparts with an mPA/Ao ratio ≤ 0.8 [16].
Statistical analysis
The statistical analysis was performed using IBM SPSS
version 23.0 software (IBM Corp., Armonk, NY, USA).
Categorical variables are presented as the frequency and
percentage and continuous variables as the median if the
distribution was normal and as the interquartile range
(IQR) if the distribution was non-normal. The GAP
score, which includes sex, age, forced vital capacity
(FVC) % predicted, and diffusing capacity of the lung for
carbon dioxide (DLCO) % predicted [17] was calculated
for each patient. The clinical characteristics of patients
with a high mPA/Ao ratio and those with a low mPA/Ao
ratio using cutoff values of 1 and 0.8 were compared by
logistic regression analysis and the results are presented
as the odds ratio and 95% confidence interval (CI). The
primary outcomes were evaluated using Kaplan-Meier
curve analysis. The association of the mPA/Ao ratio with
the outcome was analyzed by multivariate analysis using
a Cox proportional hazards model, and the results are
presented as the hazard ratio (HR) and 95% CI. P-values
≤.05 were considered to be statistically significant.
Fig. 1 Measurement of the main pulmonary artery (mPA) and
ascending aorta (Ao) diameters at the level of bifurcation of the
pulmonary artery. The diameter of the mPA was defined as the
widest diameter perpendicular to the long axis of the mPA and
measurement of the ascending Ao was taken as the
transverse diameter
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Results
Baseline characteristics
Table 1 shows the baseline characteristics of the enrolled
patients, who comprised 234 men (77.2%) and 69
women (22.8%) of mean age 67.2 ± 9.5 years. Two hun-
dred and one patients (69.6%) were current or former
smokers; these patients had a median 30-pack-year
smoking history. The most common comorbidities were
hypertension (33.0%) and diabetes mellitus (29.0%),
followed by pulmonary tuberculosis (13.2%) and emphy-
sema (12.9%). Less common diseases included ischemic
heart disease (9.6%) and congestive heart failure (3.3%).
The median GAP score was 3.0 (IQR 2.0–4.0) and
the median 6-min walking distance was 400 m (IQR
308.5–480.0). The median FVC %, forced expiratory
volume in 1 s (FEV1) %, and FEV1/FVC ratio were
74.0, 88.0, and 83.0, respectively. The median DLco %
was 69.0 (IQR 51.0–86.0). The median mPA, Ao, and
mPA/Ao ratio values were 27.9 mm (IQR 26.1–30.5),
34.2 mm (IQR 31.6–36.7), and 0.83 (IQR 0.77–0.90),
respectively.
Clinical characteristics according to mPA/Ao ratio
Table 2 shows the clinical characteristics of the patients
according to whether the mPA/Ao ratio was ≤1 or > 1.
Thirty-one patients (10.2%) had an mPA/Ao ratio > 1.0.
The median mPA diameter was 27.6 mm in the group
with an mPA/Ao ratio ≤ 1 and 32.9 mm in the group
with an mPA/Ao ratio > 1. There was no difference in
body mass index or smoking history between two
groups. Right ventricular pressure and GAP score
values were significantly higher in the group with an
mPA/Ao ratio > 1 in univariate analysis but not in
multivariate analysis.
Table 3 shows the clinical characteristics of the
patients according to whether the mPA/Ao ratio was
Table 1 Baseline characteristics of patients with idiopathic pulmonary fibrosis
Clinical characteristics n = 303
Age, years 67.2 ± 9.5
Male sex 234 (77.2%)
BMI, kg/m2, median (IQR) 22.7 (20.1–24.9)
Ever-smoker 211 (69.6%)
Smoking, pack-years, median (IQR) 30.0 (20.0–42.0)
Underlying disease
Hypertension 100 (33.0%)
Diabetes mellitus 88 (29.0%)
Pulmonary tuberculosis 43 (13.2%)
Emphysema 39 (12.9%)
Ischemic heart disease 29 (9.6%)
Congestive heart failure 10 (3.3%)
GAP score, median (IQR) 3.0 (2.0–4.0)
6MWD, m, median (IQR) 400.0 (308.5–480.0) (N = 152)
Pulmonary function at diagnosis
FVC, %, median (IQR) 74.0 (59.0–86.0)
FEV1, %, median (IQR) 88.0 (71.0–100.0)
FEV1/FVC, %, median (IQR) 83.0 (77.8–89.0)
DLCO, % 69.0 (51.0–86.0)
Echocardiography
Ejection fraction %, median (IQR) 66.0 (61.0–70.0) (N = 196)
Right ventricular pressure, mmHg, median (IQR) 28.0 (28.0–47.0) (N = 163)
Chest CT
mPA diameter, mm, median (IQR) 27.9 (26.1–30.5)
Ascending Ao diameter, mm, median (IQR) 34.2 (31.6–36.7)
mPA/Ao ratio, median (IQR) 0.83 (0.77–0.90)
The data are presented as the number (percentage) unless otherwise indicated. 6MWD, 6-min walking distance
Ao aorta, BMI body mass index, CT computed tomography, DLCO diffusing capacity of the lung for carbon dioxide, FEV1 forced expiratory volume in 1 s, FVC forced
vital capacity, IQR interquartile range, mPA main pulmonary artery
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≤0.8 or > 0.8. One hundred and eighty-two patients
(60.1%) had an mPA/Ao ratio > 0.8. The median mPA
diameter was 26.3 mm in the group with an mPA/Ao
ratio ≤ 0.8 and 29.7 mm in the group with an mPA/Ao
ratio > 0.8. In multivariate analysis, the DLCO was lower
in the group with an mPA/Ao ratio > 0.8 (odds ratio
0.97, 95% CI 0.95–0.99, P = .003). There was no signifi-
cant difference in patient age, FVC, FEV1, or echocardio-
graphic findings between the two groups.
Outcomes of IPF and associated risks
One hundred and eight patients (35.6%) died and 58
(19.1%) underwent lung transplantation during the
follow-up period. The adjusted hazard ratios from the
Cox proportional hazards analysis are shown in Table 4.
A lower body mass index (HR 0.93; 95% CI 0.89–0.97;
P < .001), a higher GAP score (HR 1.68; 95% CI 1.22–2.31;
P = .002), and a higher mPA/Ao ratio (HR 3.06; 95% CI
1.85–5.07; P < .001) were significantly associated with a
poor prognosis, including death and lung transplantation,
in patients with IPF.
Kaplan-Meier analysis of time to death or lung trans-
plantation revealed that patients with an mPA/Ao
ratio > 1.0 had a worse outcome than those with an
mPA/Ao ratio ≤ 1.0. Furthermore, the patients with an
mPA/Ao ratio > 0.8 had a worse outcome than those
with an mPA/Ao ratio ≤ 0.8 (P = .003; Fig. 2).
Discussion
The results of this study indicate that an mPA/Ao ratio > 1
is associated with worse outcomes, including death and
lung transplantation, in patients with IPF. An mPA/Ao
ratio > 0.8, which was the median value in patients with
IPF, was also associated with a poor outcome.
IPF is a specific form of chronic and progressive
fibrosing interstitial pneumonia of unknown cause, with
a reported annual incidence of 0.8–76.4 per 100,000
population [18, 19] and presents as progressive
Table 2 Clinical characteristics of patients with idiopathic pulmonary fibrosis and a main pulmonary artery to aorta diameter ratio ≤
1 and > 1
Clinical factors mPA/Ao ratio Univariable analysis Multivariable analysis
≤1 (n = 272) > 1 (n = 31) OR 95% CI P OR 95% CI P
Age, years 67.9 ± 9.1 60.4 ± 10.0 0.92 0.89–0.96 < 0.001
Sex, male 215 (79.0%) 19 (61.3%) 2.38 1.09–5.19 0.029
BMI, kg/m2 (median, IQR) 22.7 (20.2–24.9) 22.5 (19.1–26.2) 1.01 0.91–1.12 0.848
Ever-smoker 194 (71.9%) 17 (54.8%) 0.48 0.22–1.01 0.054
Underlying disease
Hypertension 94 (34.6%) 6 (19.4%) 0.45 0.18–1.15 0.095
Diabetes mellitus 82 (30.1%) 6 (19.4%) 0.56 0.22–1.41 0.215
Pulmonary tuberculosis 41 (15.1%) 2 (6.5%) 0.39 0.09–1.69 0.208
Emphysema 37 (13.7%) 2 (6.5%) 0.44 0.10–1.91 0.270
Ischemic heart disease 28 (10.3%) 1 (3.2%) 0.29 0.04–2.21 0.233
Congestive heart failure 10 (3.7%) 0 (0%)
GAP score 3.11 ± 1.24 3.75 ± 1.26 1.57 1.08–2.27 0.018 1.53 0.69–3.40 0.298
6 MW distance, m (median, IQR) 410.0 (322.5–480.0) 232.5 (95.0–555.8) 0.99 0.99–1.00. 0.032 0.99 0.99–1.00 0.190
PFT at diagnosis
FVC, % predicted, (median, IQR) 75.0 (61.0–86.3) 55.0 (44.5–72.0) 0.95 0.93–0.98 < 0.001
FEV1, % predicted, (median, IQR) 89.5 (73.0–100.0) 64.0 (51.5–81.0) 0.96 0.95–0.98 < 0.001 1.07 0.99–0.15 0.074
DLCO, % 70.9 ± 23.8 48.4 ± 23.1 0.96 0.94–0.98 < 0.001
Echocardiography
EF, %, (median, IQR) 65.0 (61.0–69.0) 67.0 (64.0–71.0) 1.08 1.01–1.14 0.022 1.09 0.93–1.27 0.285
RVP, mmHg, (median, IQR) 37.0 (27.8–46.0) 43.0 (33.0–52.5) 1.03 1.01–1.06 0.014 1.04 0.99–1.10 0.113
Chest CT
mPA diameter, mm, (median, IQR) 27.6 (25.8–29.8) 32.9 (29.8–35.1) 1.38 1.23–1.54 < 0.001
Ascending Ao diameter, mm, (median, IQR) 34.5 (32.0–36.9) 29.8 (27.7–32.8) 0.71 0.62–0.80 < 0.001
The data are presented as the number (percentage) unless otherwise indicated. 6MWD, 6-min walking distance
Ao aorta, BMI body mass index, CI confidence interval, DLCO diffusing capacity, EF ejection fraction, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity,
IQR interquartile range, mPA main pulmonary artery, OR odds ratio, PFT pulmonary function tests, RVP right ventricular pressure
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aggravation of dyspnea and decreasing lung function.
The prognosis for patients with IPF is poor, with a me-
dian survival of 2.5–3.5 years [2, 20, 21]. PH is common
in patients with IPF and is also associated with an
increased risk of death and a poor outcome [22–24]. In
a previous study, the prevalence of PH in patients with
IPF listed for lung transplantation was 32% by right
heart catheterization, and there was a linear correlation
between the mortality risk and mean pulmonary artery
pressure [1].
In our study, univariate analysis revealed a relationship
between a higher mPA/Ao ratio and a higher right ven-
tricular pressure in patients with IPF. Although we could
not perform right heart catheterization as part of our
study, a higher right ventricular pressure is a known
manifestation of PH [25, 26], so an association between
the mPA/Ao ratio and PH is likely in patients with IPF.
This finding is similar to those in previous studies in
other pulmonary diseases [7, 9, 27, 28]. Iyer et al.
reported that an mPA/Ao ratio > 1 on a CT scan in
patients with COPD correlated with invasive measure-
ments of pulmonary artery pressure and the presence
of PH [29]. Schmidt et al. also reported that esti-
mation of pulmonary artery diameter on chest CT
could predict the presence of PH in patients with
chronic pulmonary embolism [30].
Table 3 Clinical characteristics of patients with idiopathic pulmonary fibrosis and a main pulmonary artery to aorta diameter ratio ≤
0.8 and > 0.8
Clinical factors mPA/Ao ratio Univariate analysis Multivariate analysis
≤ 0.8 (n = 121) > 0.8 (n = 182) OR 95% CI P OR 95% CI P
Age, years 68.7 ± 8.3 66.1 ± 10.0 0.97 0.95–1.00 0.019 0.96 0.91–1.01 0.136
Sex, male 102 (84.3%) 132 (72.5%) 2.03 1.13–3.66 0.018
BMI, kg/m2, (median, IQR) 23.2 (20.8–26.6) 22.4 (19.8–24.8) 0.96 0.91–1.03 0.247
Ever-smoker 91 (75.8%) 120 (66.3%) 0.63 0.37–1.05 0.078
Underlying disease
Hypertension 40 (33.1%) 60 (33.0%) 1.00 0.61–1.62 0.987
Diabetes mellitus 30 (24.8%) 58 (31.9%) 1.42 0.85–2.38 0.185
Pulmonary tuberculosis 15 (12.4%) 28 (15.4%) 1.29 0.66–2.52 0.466
Emphysema 19 (15.7%) 20 (11.0%) 0.67 0.34–1.31 0.240
Ischemic heart disease 8 (6.6%) 21 (11.5%) 1.84 0.79–4.31 0.158
Congestive heart failure 2 (1.7%) 8 (4.4%) 2.74 0.57–13.1 0.208
GAP score 3.07 ± 1.16 3.24 ± 1.31 1.12 0.91–1.37 0.280
6 MW distance, m (median, IQR) 415.0 (356.3–477.5) 400.0 (246.3–480.0) 0.99 0.99–1.00 0.107
PFT at diagnosis
FVC, % predicted, (median, IQR) 77.0 (63.0–90.5) 71.0 (55.0–83.0) 0.98 0.96–0.99 < 0.001 1.01 0.97–1.05 0.735
FEV1, % predicted, (median, IQR) 94.0 (76.0–101.0) 83.0 (66.0–98.5) 0.98 0.97–0.99 < 0.001 1.01 0.97–1.04 0.805
DLCO, % 77.1 ± 23.6 62.7 ± 23.6 0.97 0.96–0.99 < 0.001 0.97 0.95–0.99 0.002
Echocardiography
EF, %, (median, IQR) 64.0 (60.0–69.0) 66.0 (62.0–70.0) 1.02 0.99–1.05 0.294 1.16 0.93–1.45 0.187
RVP, mmHg, (median, IQR) 34.4 (25.0–43.0) 40.0 (31.5–48.0) 1.03 1.00–1.05 0.038 1.01 0.98–1.05 0.485
Chest CT
mPA diameter, mm, (median, IQR) 26.3 (24.5–27.9) 29.7 (27.1–31.9) 1.49 1.34–1.65 < 0.001
Ascending aorta diameter,
mm, (median, IQR)
35.7 (33.9–37.7) 32.7 (30.4–35.0) 0.75 0.69–0.82 < 0.001
The data are presented as the number (percentage) unless otherwise indicated. 6MWD, 6-min walking distance
Ao aorta, CT computed tomography, DLCO diffusing capacity, EF ejection fraction, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, IQR interquartile
range, mPA main pulmonary artery, PFT pulmonary function test, RVP right ventricular pressure
Table 4 Clinical characteristics associated with death or lung
transplantation in patients with idiopathic pulmonary fibrosis
(multivariate analysis)
Variable Hazard ratio 95% CI P-value
BMI, kg/m2 0.925 0.887–0.965 < 0.001
GAP score 1.676 1.218–2.306 0.002
mPA/Ao ratio 3.062 1.849–5.071 < 0.001
Ao aorta, BMI body mass index, CI confidence interval, mPA main
pulmonary artery
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We found a statistically difference in the GAP score
between the group with an mPA/Ao ratio > 1.0 and the
group with an mPA/Ao ratio ≤ 1.0 in univariate analysis.
The components of the GAP score, i.e., sex, age, FVC %
predicted, and DLco % predicted, have been validated as
prognostic factors in patients with IPF [17, 31–33]. Fur-
thermore, in our study, the mPA/Ao ratio was associated
with a poor outcome, including death or lung trans-
plantation, in patients with IPF. Overall, our findings
suggest that the mPA/Ao ratio could be used to predict
the prognosis of IPF and the associated risks, which is in
agreement with previous reports. Shin et al. reported
that an mPA/Ao ratio > 1 was associated with poor out-
comes in Western patients with IPF and that calculation
of the mPA/Ao ratio on chest CT might be used for risk
stratification in these patients [14]. Similar results have
been reported in patients with COPD. A high mPA/Ao
ratio was associated with severe exacerbations of
COPD [34] and was an independent predictor of
mortality [35]. Given the results in patients with
COPD, a high mPA/Ao ratio in patients with IPF
could be related to acute exacerbation in addition to
the possibility of PH.
We also investigated the prognostic value of the mPA/Ao
ratio when based on a cutoff of 0.8. An mPA/Ao ratio > 0.8
was also associated with a worse outcome than an mPA/Ao
ratio ≤ 0.8 in patients with IPF. One Korean study reported
a mean mPA/Ao ratio of 0.87 and another reported an
mPA/Ao ratio > 0.8 to be a risk factor for exacerbation of
COPD [15, 16]. These results can be explained by
differences in the body mass index, lifestyle factors,
and/or the distribution of mPA/Ao values in the study
populations. Therefore, a borderline mPA/Ao ratio in
a Korean patient with IPF may have adverse clinical
implications in terms of the prognosis. Our findings
suggest that patients with IPF and an mPA/Ao ratio > 0.8
require close observation, including short-term follow-up
evaluation with chest CT and PFT results as well as early
consideration for lung transplantation in view of their
poor prognosis.
This study had several limitations. The first is that it
was conducted retrospectively at a single center. Fur-
thermore, some data that might have influenced the
results were missing, and several examinations, inclu-
ding transthoracic echocardiography and 6-min walking
distance, were not performed in all patients. Second,
there might have been some variation in the mPA and
Ao measurements obtained on chest CT depending on
the reviewer. However, we tried to overcome this limita-
tion by having two reviewers measure the diameters of
the mPA and Ao independently. Third, the proportion
of patients who underwent transplantation was relatively
high at our center, which could have introduced a degree
of bias when evaluating the outcome. Fourth, we did not
perform right heart catheterization, so it was not pos-
sible to correlate the hemodynamics with the mPA/Ao
ratio on CT in detail. Nevertheless, our study also has
some strengths, in that it shows that a high mPA/Ao
ratio could be a prognostic factor in Asian patients
with IPF and that a borderline mPA/Ao value could be
clinically meaningful in these patients. Our findings
may be relevant to patients when they are initially
diagnosed with IPF, although prospective studies are
needed for validation.
Fig. 2 Kaplan-Meier analysis of time to death or lung transplantation in patients with idiopathic pulmonary fibrosis according to whether
the ratio of the diameter of the main pulmonary artery to that of the aorta on chest computed tomography was a ≤1.0 or > 1 or b ≤0.8
or > 0.8 (P < .001)
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Conclusions
We have identified that the mPA/Ao ratio on chest CT
at the time of initial diagnosis of IPF has prognostic
implications. An mPA/Ao ratio > 1 was associated with poor
outcome in patients with IPF. In addition, an mPA/Ao
ratio > 0.8 can be considered an early adverse prognos-
tic factor in these patients. We suggest that the diame-
ters of the mPA and Ao should be measured on chest
CT at the time of initial diagnosis of IPF and that
patients found to have a higher mPA/Ao ratio be kept
under close observation.
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